PAREXEL INTL CORP (PRXL) Stock News
NASDAQ:PRXL - Nasdaq - US6994621075
PRXL Latest News, Press Relases and Analysis
Parexel Said to Draw Interest From AmerisourceBergen, PE Firms
Parexel International Corp., a pharmaceutical services company for sale, has drawn interest from suitors including AmerisourceBergen Corp., according to people familiar with the matter.
Mentions: ABC
Parexel’s Owner Weighs Sale of Drug-Testing Company
The owner of Parexel International Corp., which helps drugmakers run clinical trials, is working with an adviser on a potential sale that could value the company at several billion dollars, according to people familiar with the matter.
With Hurricane Harvey, We Are in The Cross-Hairs of Volatility: Market Recon
PAREXEL Launches Perceptive® Cloud for the Life Sciences Industry
PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry
Pamplona Capital Management Completes Acquisition of PAREXEL International
Diagnostics And Tools Revisited: Sector Outperformance That Tracks Biotech
Life science tools and services stocks have outperformed biopharmaceuticals with less volatility.
Stock Performance Review on Medical Labs & Research Industry -- PAREXEL, China Cord Blood, ICON, and PRA Health Sciences
Six Flags Entertainment and Sterling Bancorp Set to Join S&P MidCap 400; Oil States Intl. and KEMET to Join S&P SmallCap 600
These life-science stocks provide biotech-like performance without the gyrations
Life-science equipment-and-service providers have retuned as much as 60% this year. By Phil van Doorn.
These life-science stocks provide biotech-like performance without the gyrations
Life-science equipment-and-service providers have retuned as much as 60% this year. By Phil van Doorn.
PAREXEL International Receives Shareholder Approval for Proposed Acquisition by Pamplona Capital Management
PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments
PAREXEL International Corporation (PRXL): Earnings News
PRXL – Beats Wall Street consensus EPS estimates by $0.09 and beats on revenues.
PAREXEL International Reports Fourth Quarter and Fiscal Year 2017 Results
5 Stocks To Watch For August 28, 2017
Some of the stocks that may grab investor focus today are:
Wall Street expects Standex Int'l Corp. (NYSE: SXI) to report ...
Earnings Scheduled For August 28, 2017
Companies Reporting Before The Bell
Standex Int'l Corp. (NYSE: SXI) is projected to report quarterly earnings at $1.36 ...
PAREXEL International Announces Date of Fourth Quarter and Fiscal Year 2017 Earnings Release
PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of PAREXEL International Corporation - PRXL
PAREXEL International Corporation Announces $720 Million Senior Notes Offering by West Street Merger Sub, Inc.
Two PAREXEL Executives Named to 2017 PharmaVOICE 100
PAREXEL Receives CEO Cancer Gold Standard Re-Accreditation
PAREXEL Named to the Forbes America’s Best Employers List for Second Consecutive Year
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of PAREXEL International Corporation and Encourages Investors to Contact the Firm for Additional Information
PAREXEL INTERNATIONAL CORPORATION SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to Pamplona Capital Management, LLP
Harwood Feffer LLP Announces Investigation of PAREXEL International Corporation
PAREXEL INTERNATIONAL CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PAREXEL ALERT: J&W Investigates Proposed Sale of PAREXEL International; Is $88.10 a Fair Price?
PAREXEL International Enters Definitive Agreement to Be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash
PAREXEL Introduces Its Connected Journey™ of Newly Integrated Data-Driven Services to Simplify Drug Development and Commercialization